Notable Labs’ attempts to take a Boehringer Ingelheim cancer drug to market appear to have come to end with the ...

In patients with moderate to severe Crohn’s disease, guselkumab showed similar efficacy in both biologic-naive and ...

Boehringer Ingelheim has opened a €60m ($66.8m) research building in Vienna, Austria, as the company looks to double down in the oncology therapeutics space. The building is named after Angelika ...

John Maraganore, the former CEO of Alnylam Pharmaceuticals, launched City Therapeutics, a new startup with $135 million from ...

Boehringer Ingelheim says it is on track to launch 25 new treatments in its human pharma division onto the market between now and 2030, fuelled by an R&D pipeline that it says is the best in its ...

She's currently the Chief Medical Officer and Head of Medicine at Boehringer Ingelheim. Well, Dr. Hinsch Gylvin. Thanks for joining me today. That really has changed. So first and foremost ...

Zoetis excels in innovation, creating new categories and consistently raising the standard of care, outperforming competitors ...

By Noah Weiland and Rebecca Robbins Hikma said it had reduced the cash portion of the offer as Boehringer Ingelheim’s generic drugs business in the U.S. had lower-than-expected sales.

Researchers from the School of Veterinary Medicine and Perelman School of Medicine have found that YY1 knockout pro-B cells can generate T lineage cells helping B cells produce antibodies.

This year’s honorees, Boehringer Ingelheim and GSK, have set new standards in sustainable manufacturing. Boehringer Ingelheim’s team created a highly efficient 3-step synthesis for Spiroketone CD 7659 ...